Silencing of the HER2/neu gene by siRNA inhibits proliferation and induces apoptosis in HER2/neu-overexpressing breast cancer cells

被引:123
作者
Faltus, T [1 ]
Yuan, JP [1 ]
Zimmer, B [1 ]
Krämer, A [1 ]
Loibl, S [1 ]
Kaufmann, M [1 ]
Strebhardt, K [1 ]
机构
[1] Univ Frankfurt, Dept Obstet & Gynecol, Sch Med, D-60590 Frankfurt, Germany
来源
NEOPLASIA | 2004年 / 6卷 / 06期
关键词
HER2/neu; RNA interference; siRNA; antiproliferative activity; apoptosis;
D O I
10.1593/neo.04313
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In eukaryotes, double-stranded (ds) RNA induces sequence-specific inhibition of gene expression referred to as RNA interference (RNAi). We exploited RNAi to define the role of HER2/neu in the neoplastic proliferation of human breast cancer cells. We transfected SK-BR-3, BT-474, MCF-7, and MDA-MB-468 breast cancer cells with short interfering RNA (siRNA) targeted against human HER2/neu and analyzed the specific inhibition of HER2/neu expression by Northern and Western blots. Transfection with HER2/neu-specific siRNA resulted in a sequence-specific decrease in HER2/neu mRNA and protein levels. Moreover, transfection with HER2/neu siRNA caused cell cycle arrest at G(0)/G(1) in the breast cancer cell lines SK-BR-3 and BT-474, consistent with a powerful RNA silencing effect. siRNA treatment resulted in an anti proliferative and apoptotic response in cells overexpressing HER2/neu, but had no influence in cells with almost no expression of HER2/neu proteins like MDA-MB-468 cells. These data indicate that HER2/neu function is essential for the proliferation of HER2/neu-overexpressing breast cancer cells. Our observations suggest that siRNA targeted against human HER2/neu may be valuable tools as antiproliferative agents that display activity against neoplastic cells at very low doses.
引用
收藏
页码:786 / 795
页数:10
相关论文
共 45 条
[1]   Phase II study of weekly intravenous recombinant humanized Anti-p185(HER2) monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast [J].
Baselga, J ;
Tripathy, D ;
Mendelsohn, J ;
Baughman, S ;
Benz, CC ;
Dantis, L ;
Sklarin, NT ;
Seidman, AD ;
Hudis, CA ;
Moore, J ;
Rosen, PP ;
Twaddell, T ;
Henderson, IC ;
Norton, L .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (03) :737-744
[2]  
BENZ CC, 1993, BREAST CANCER RES TR, V24, P85
[3]   OVEREXPRESSION OF HER-2 NEU IN ENDOMETRIAL CANCER IS ASSOCIATED WITH ADVANCED STAGE DISEASE [J].
BERCHUCK, A ;
RODRIGUEZ, G ;
KINNEY, RB ;
SOPER, JT ;
DODGE, RK ;
CLARKEPEARSON, DL ;
BAST, RC .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1991, 164 (01) :15-21
[4]  
BERCI G, 1990, POSTGRAD GEN SURG, V2, P50
[5]   REDUCTION OF ERBB2 GENE-PRODUCT IN MAMMA CARCINOMA CELL-LINES BY ERBB2 MESSENGER-RNA-SPECIFIC AND TYROSINE KINASE CONSENSUS PHOSPHOROTHIOATE ANTISENSE OLIGONUCLEOTIDES [J].
BERTRAM, J ;
KILLIAN, M ;
BRYSCH, W ;
SCHLINGENSIEPEN, KH ;
KNEBA, M .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1994, 200 (01) :661-667
[6]   Cell-cell adhesion mediated by binding of membrane-anchored ligand LERK-2 to the EPH-related receptor human embryonal kinase 2 promotes tyrosine kinase activity [J].
Bohme, B ;
Vandenbos, T ;
Cerretti, DP ;
Park, LS ;
Holtrich, U ;
RubsamenWaigmann, H ;
Strebhardt, K .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (40) :24747-24752
[7]  
Brodowicz T, 1997, INT J CANCER, V73, P875, DOI 10.1002/(SICI)1097-0215(19971210)73:6<875::AID-IJC19>3.0.CO
[8]  
2-3
[9]   HUMANIZATION OF AN ANTI-P185HER2 ANTIBODY FOR HUMAN CANCER-THERAPY [J].
CARTER, P ;
PRESTA, L ;
GORMAN, CM ;
RIDGWAY, JBB ;
HENNER, D ;
WONG, WLT ;
ROWLAND, AM ;
KOTTS, C ;
CARVER, ME ;
SHEPARD, HM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (10) :4285-4289
[10]   Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I and induces apoptosis of Her2/neu positive tumor cell lines [J].
Choudhury, A ;
Charo, J ;
Parapuram, SK ;
Hunt, RC ;
Hunt, DM ;
Seliger, B ;
Kiessling, R .
INTERNATIONAL JOURNAL OF CANCER, 2004, 108 (01) :71-77